LINDA DEMO: Open Payments
NPI 1366944399 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$743 in 28 payments from 12 companies in 2025. Trend: 2023 $124 · 2024 $129 · 2025 $743
Food & beverage: $743
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $160 |
| Neurocrine BioSciences, Inc. | 1 | $128 |
| Alkermes, Inc. | 1 | $110 |
| Axsome Therapeutics, Inc. | 4 | $95 |
| Collegium Pharmaceutical, Inc. | 4 | $64 |
| Janssen Pharmaceuticals, Inc | 2 | $53 |
| Tris Pharma Inc | 2 | $38 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| ABBVIE INC. | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $15 |
Products named: REXULTI, INGREZZA, LYBALVI, Auvelity, Jornay PM, SPRAVATO, Dyanavel XR, CAPLYTA.
Industry payments across IN — which companies pay providers there.
